—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Apellis Pharmaceuticals Inc (APLS) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for APLS, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 62/100 · S&P 500 fund at 67, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-25
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +8.4% over 20 sessions. Factor regime → 2026-09-25
  • Sovereign pressure Index 0.61 · up 0.29 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-25
How it trades on rate days beta 0.52 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How APLS has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.52 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Apellis Pharmaceuticals Inc moved 0.52% on average · correlation 0.09 · higher than 54% of US names
  • Beta, last 3 months −0.28 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.94% on average against −0.74% for the S&P 500 the 6 sessions of the past year in which TLT fell most, i.e. long yields rose most

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · United States · 8 names with week and year-to-date

Peer group

Biotechnology · United States

This name carries no Closelooknet score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against APLS on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Apellis Pharmaceuticals Inc

APLS in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Apellis Pharmaceuticals discovers, develops and sells medicines for diseases that have few existing treatments. Its marketed products are Empaveli, used for paroxysmal nocturnal hemoglobinuria, and Syfovre, used for geographic atrophy linked to age-related macular degeneration. It is also testing Empaveli in several kidney disorders and working on an RNA-based therapy for geographic atrophy, alongside early gene-editing research done with Beam Therapeutics. The drug behind both approved products, pegcetacoplan, is licensed outside the United States to Swedish Orphan Biovitrum. Based in Waltham, Massachusetts, the company now operates as a subsidiary of Biogen.
Where it sits in the stack
Apellis carries no seat in our AI build-out index; it sits in the healthcare sleeve of our universe, within biotechnology, and has no place in any hardware or software layer of the stack.
Who it is priced against
Closelooknet's peer group carries no entry for Apellis; the market compares it with other complement-pathway drug developers, and increasingly with Biogen, its new parent.
Why Closelooknet tracks it
Apellis holds a seat in the Russell 1000. It carries no Closelooknet score yet, does not sit in our AI build-out index, and has not appeared in any of the diary's published editions.
What the diary watches
Closelooknet watches how the move under Biogen's ownership affects commercial execution for Syfovre and Empaveli, and whether pipeline work on kidney indications and the RNA-based programme continues at its prior pace.

Apellis Pharmaceuticals Inc (APLS) trades on US exchanges.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

FAQ · from the current data · as of 2026-09-26

Quick answers

What is Apellis Pharmaceuticals Inc (APLS)?

Apellis Pharmaceuticals Inc trades as APLS on the US exchange (United States) in the Closelooknet research universe, as of the registry build of 2026-09-26.

Is APLS in a Closelooknet index?

Not currently — Apellis Pharmaceuticals Inc is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-09-26.

Where does APLS trade against its moving averages?

Downtrend stack: Trades -2.3% vs the 50-day and -81.1% vs the 200-day average, 92.2% below the 52-week high and +5.6% off the 52-week low; a death cross printed 59 sessions ago. Computed from daily closes. As of 2026-09-04 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Apellis Pharmaceuticals Inc trade when bond yields rise?

Over the past year Apellis Pharmaceuticals Inc had a beta of 0.52 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 54% of US names. On the 6 sessions in which long bonds fell most it moved −0.94% on average, against −0.74% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does Apellis Pharmaceuticals Inc do?

Apellis Pharmaceuticals discovers, develops and sells medicines for diseases that have few existing treatments. Its marketed products are Empaveli, used for paroxysmal nocturnal hemoglobinuria, and Syfovre, used for geographic atrophy linked to age-related macular degeneration. It is also testing Empaveli in several kidney disorders and working on an RNA-based therapy for geographic atrophy, alongside early gene-editing research done with Beam Therapeutics. Closelooknet's peer group carries no entry for Apellis; the market compares it with other complement-pathway drug developers, and increasingly with Biogen, its new parent.

Where does Apellis Pharmaceuticals Inc sit in the AI build-out?

Apellis carries no seat in our AI build-out index; it sits in the healthcare sleeve of our universe, within biotechnology, and has no place in any hardware or software layer of the stack. Apellis holds a seat in the Russell 1000. It carries no Closelooknet score yet, does not sit in our AI build-out index, and has not appeared in any of the diary's published editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for APLS, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.